Board-certified pulmonologist and immunologist from the University of Paris with a Master Degree in Clinical Pharmacology and Pharmacokinetics, whose first career part was spent in various university hospitals, as a Clinical Assistant Professor of Respiratory Medicine, then Head of a Respiratory Medicine Department, with a fellow-researcher position at INSERM.
Yannick PLETAN joined the pharmaceutical industry at Sanofi as Head of Global Immunology R&D, then moved to Pierre Fabre Research Institute as Chief Medical Officer, Global Head of Clinical Development and of R&D Strategy. In these positions, I have conducted the development and registration of several new molecular entities on a worldwide basis. He then worked for Pfizer as VP-Head of the French Medical & Scientific Division, Member of the Country Executive Committee, and up until 2016 as Country Medical Director of Roche in France as well as a Member of the Global Medical Affairs Council of Hoffmann-Laroche in Basel. He co-founded the Roche Research Institute for public-private partnership, and founded the Roche Foundation for Personalized HealthCare in Strasbourg (France). During these years spent in the Pharma industry, Dr PELTAN has been involved in the successful development/launch of 5 out of the 10 best-WW-selling drugs. He left the big pharma industry in 2016 in order to launch his own activity in the biotech and joined DEINOVE as Chief Medical Officer.
Yannick PLETAN was author or co-author of several international guidelines for WHO and later ICH, and of various publications on clinical trial methodology. He is or has been over the past years a Guest Lecturer / Visiting Professor to several Universities or Institutions (e.g., ESSEC) in EU and USA (the University of Davies, California), a co-founder of and lecturer to the European Diploma of Pharmaceutical Medicine (Lyon 1 University), and more recently a co-founder of a private Master Degree for Pharma Industry physicians. He is involved in research works on the use of Data Science in translational research. He seats in the Board of a few public and private biotech companies.